A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Description

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Conditions

Healthy Volunteer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Assessment of the Relative Bioavailability of ABBV-932 Formulations in Healthy Adult Subjects

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Condition
Healthy Volunteer
Intervention / Treatment

-

Contacts and Locations

Grayslake

Acpru /Id# 266649, Grayslake, Illinois, United States, 60030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG
  • * History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • * History of any clinically significant sensitivity or allergy to any medication or food.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

AbbVie,

ABBVIE INC., STUDY_DIRECTOR, AbbVie

Study Record Dates

2025-12